このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Olfactory Function in Patients With Sinonasal Diseases: A Multicenter Observational Study

2026年11月10日 更新者:Gustavo Subtil Magalhães Freire、University of Brasilia

Olfactory Profile of Patients With Sinonasal Diseases: A Multicenter Cross-Sectional Observational Study in Brazil

This multicenter, cross-sectional observational study aims to characterize olfactory function in patients with sinonasal diseases and investigate its associations with disease severity, clinical characteristics, and inflammatory markers. Olfactory function will be assessed using the MultiScent-20 digital odor identification test. Additional assessments will include sinonasal symptom severity, quality of life, endoscopic and radiological findings, and clinical and laboratory markers suggestive of type 2 inflammation. Healthy volunteers without olfactory complaints will serve as a comparison group. The study is expected to enroll 3,800 participants across participating centers in Brazil.

調査の概要

詳細な説明

This is a multicenter, cross-sectional observational study conducted in Brazilian outpatient otolaryngology settings. The study aims to investigate olfactory function in patients with chronic rhinosinusitis and other sinonasal diseases and to explore its associations with clinical manifestations, disease severity, and inflammatory characteristics.

Olfactory function will be objectively assessed using the MultiScent-20 digital odor identification test, which provides a score ranging from 0 to 20, with higher scores indicating better olfactory performance. Participants will undergo a single study assessment.

Clinical data will include sinonasal symptoms, SNOT-22 scores, visual analog scale ratings, nasal polyp scores, previous sinonasal surgeries, relevant comorbidities, and alcohol intolerance. Laboratory, histopathological, and imaging findings obtained during routine clinical care within the predefined eligibility window will be collected when available.

Criteria suggestive of type 2 inflammation will be evaluated using predefined clinical and laboratory characteristics. Missing clinical or laboratory information will not constitute an exclusion criterion. Analyses involving individual variables will include participants with the corresponding available data, whereas the total count of type 2 inflammatory criteria will be calculated only when all eight criteria have been assessed.

A comparison group of healthy volunteers without olfactory complaints will also be included. No therapeutic intervention will be administered as part of this observational study.

研究の種類

観察的

入学 (推定)

3800

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • Estado de Bahia
      • Salvador、Estado de Bahia、ブラジル
        • 募集
        • Hospital Universitário Professor Edgard Santos (HUPES)
    • Federal District
      • Brasília、Federal District、ブラジル
        • 募集
        • Hospital Universitário de Brasília (HUB)
    • Goiás
      • Goiânia、Goiás、ブラジル
        • 募集
        • Hospital das Clínicas da UFG
    • Paraná
      • Curitiba、Paraná、ブラジル
        • 募集
        • Hospital IPO - sede Água Verde
    • Pernambuco
      • Recife、Pernambuco、ブラジル
        • 募集
        • Hospital das Clínicas da UFPE
    • Piauí
      • Teresina、Piauí、ブラジル
        • 募集
        • Hospital Getúlio Vargas (HGV)
    • Rio Grande do Sul
      • Canoas、Rio Grande do Sul、ブラジル
        • 募集
        • Hospital Universitário Canoas
      • Porto Alegre、Rio Grande do Sul、ブラジル
        • 募集
        • Hospital de Clínicas de Porto Alegre (HCPA)
    • Rio de Janeiro
      • Rio de Janeiro、Rio de Janeiro、ブラジル
        • 募集
        • Hospital Universitário Pedro Ernesto
    • São Paulo
      • Ribeirão Preto、São Paulo、ブラジル
        • 募集
        • Hospital das Clínicas da FMRP-USP - Campus
      • São Paulo、São Paulo、ブラジル
        • 募集
        • Hospital das Clínicas da FMUSP
      • São Paulo、São Paulo、ブラジル
        • 募集
        • Hospital São Paulo - Hospital Universitário da UNIFESP

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

はい

受講資格のある性別

全て

サンプリング方法

非確率サンプル

調査対象母集団

Adults aged 18 years or older with chronic rhinosinusitis or other sinonasal diseases and healthy volunteers without olfactory complaints, recruited at participating outpatient centers in Brazil.

説明

Inclusion Criteria:

Adults aged 18 years or older. Patients with chronic rhinosinusitis or other sinonasal diseases, or healthy volunteers without olfactory complaints participating in the comparison group.

Ability to understand and complete the study assessments.

Exclusion Criteria:

Illiteracy. Respiratory tract infection within the preceding seven days. Sinonasal surgery within the preceding six months. History of severe head trauma. Diagnosis of a neurodegenerative disease.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 観測モデル:OTHER
  • 時間の展望:CROSS_SECTIONAL

コホートと介入

グループ/コホート
Sinonasal Disease Participants

Adults with chronic rhinosinusitis or other sinonasal diseases.

Healthy Comparison Participants

Healthy adults without olfactory complaints.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
MultiScent-20 odor identification score
時間枠:Once at enrollment (cross-sectional assessment).

Total number of correctly identified odors on the 20-item MultiScent-20 digital odor identification test. Scores range from 0 to 20; higher scores indicate better odor identification performance.

Once at enrollment (cross-sectional assessment).

二次結果の測定

結果測定
メジャーの説明
時間枠
Sinonasal Outcome Test-22 (SNOT-22) total score
時間枠:Once at enrollment (cross-sectional assessment).

Patient-reported sinonasal symptom burden assessed using the 22-item SNOT-22 questionnaire. Total scores range from 0 to 110; higher scores indicate greater symptom burden.

Once at enrollment (cross-sectional assessment).
Severity of four sinonasal symptoms on visual analog scales
時間枠:Once at enrollment (cross-sectional assessment).

Severity will be assessed separately for nasal obstruction, rhinorrhea, facial pain or pressure, and olfactory dysfunction using four individual visual analog scales (VAS). Each score ranges from 0 (no symptoms) to 10 (maximum symptom intensity). Each symptom score will be analyzed in relation to the MultiScent-20 odor identification score. No combined VAS total score is prespecified.

Once at enrollment (cross-sectional assessment).
Nasal Polyp Score (NPS)
時間枠:At enrollment, using available routine clinical assessment.

Endoscopic nasal polyp burden assessed using the Nasal Polyp Score, ranging from 0 to 8; higher scores indicate greater polyp burden. Applicable to participants with available endoscopic assessment.

At enrollment, using available routine clinical assessment.
Lund-Mackay computed tomography score
時間枠:At enrollment; CT performed within the 12 months preceding enrollment, if available.

Extent of sinonasal opacification on computed tomography evaluated using the Lund-Mackay scoring system (total score 0-24; higher scores indicate more extensive radiologic disease). Assessed when routine-care imaging is available.

At enrollment; CT performed within the 12 months preceding enrollment, if available.
Peripheral blood eosinophil count
時間枠:At enrollment; routine-care laboratory test performed within the 12 months preceding enrollment, if available.

Absolute peripheral blood eosinophil count obtained from available routine-care laboratory testing.

At enrollment; routine-care laboratory test performed within the 12 months preceding enrollment, if available.
Total serum immunoglobulin E (IgE)
時間枠:At enrollment; routine-care laboratory test performed within the 12 months preceding enrollment, if available.

Total serum IgE concentration obtained from available routine-care laboratory testing.

At enrollment; routine-care laboratory test performed within the 12 months preceding enrollment, if available.
Number of clinical and laboratory criteria suggestive of type 2 inflammation in chronic rhinosinusitis
時間枠:Once at enrollment, using clinical data and available routine-care tests obtained within the preceding 12 months when applicable.

Count of predefined clinical and laboratory criteria suggestive of type 2 inflammation in chronic rhinosinusitis, according to the guideline for use of biologics in chronic rhinosinusitis with nasal polyps cited in the study protocol. Clinical criteria: symptom onset between ages 30 and 50 years; marked improvement in olfaction following oral corticosteroid use; adult-onset asthma; aspirin or nonsteroidal anti-inflammatory drug intolerance; and bilateral nasal polyps associated with thick allergic- or eosinophilic-appearing nasal mucus, preferably confirmed by nasal endoscopy. Biomarker criteria: tissue eosinophils ≥10 cells/high-power field; blood eosinophils ≥250 cells/µL; or total serum IgE ≥100 IU/mL. The total number of criteria suggestive of type 2 inflammation will be calculated only for participants with complete data on all eight clinical and laboratory criteria. The count ranges from 0 to 8 and equals the number of positive criteria.

Once at enrollment, using clinical data and available routine-care tests obtained within the preceding 12 months when applicable.
Presence of selected comorbidities
時間枠:Once at enrollment (cross-sectional assessment).

Presence or absence of relevant comorbidities, including asthma and aspirin-exacerbated respiratory disease (AERD), recorded from clinical history.

Once at enrollment (cross-sectional assessment).
Number of previous sinonasal surgeries
時間枠:Once at enrollment (cross-sectional assessment).

The number of previous sinonasal surgeries will be recorded for each participant.

Once at enrollment (cross-sectional assessment).
Alcohol intolerance
時間枠:Once at enrollment (cross-sectional assessment).

Alcohol intolerance will be assessed as a binary variable (yes/no), based on self-reported nasal symptoms following the consumption of alcoholic beverages.

Once at enrollment (cross-sectional assessment).

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Gustavo Subtil M. Freire、University of Brasilia

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2025年3月1日

一次修了 (推定)

2027年11月1日

研究の完了 (推定)

2027年11月1日

試験登録日

最初に提出

2026年11月10日

QC基準を満たした最初の提出物

2026年11月10日

最初の投稿 (実際)

2026年11月17日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月17日

QC基準を満たした最後の更新が送信されました

2026年11月10日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • UNB-OLFATO-RSC-2026
  • 68687423.5.0000.5558 (その他の識別子:Brazilian Research Ethics CAAE)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

未定

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する